HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anacetrapib.

Abstract
Merck & Co. is developing anacetrapib (MK 0859; MK-0859; MK0859), a selective cholesterol ester transfer protein (CETP) inhibitor, as a treatment for atherosclerosis, hypercholesterolemia, and mixed dyslipidemia. Add-on therapy with anacetrapib is currently being evaluated in a 76-week phase III trial in patients with coronary heart disease (CHD) or CHD risk-equivalent disease in the US, Germany, Spain, and Austria. This review discusses the development history and scientific profile of this new compound.
Authors
JournalAmerican journal of cardiovascular drugs : drugs, devices, and other interventions (Am J Cardiovasc Drugs) Vol. 10 Issue 4 Pg. 267-70 ( 2010) ISSN: 1175-3277 [Print] New Zealand
PMID20653333 (Publication Type: Journal Article)
Chemical References
  • Cholesterol Ester Transfer Proteins
  • Oxazolidinones
  • anacetrapib
Topics
  • Atherosclerosis (drug therapy)
  • Cholesterol Ester Transfer Proteins (adverse effects, antagonists & inhibitors)
  • Clinical Trials as Topic
  • Coronary Disease (drug therapy, physiopathology)
  • Dyslipidemias (drug therapy)
  • Humans
  • Hypercholesterolemia (drug therapy)
  • Oxazolidinones (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: